Patents by Inventor Llorenc Rafecas
Llorenc Rafecas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9738607Abstract: The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.Type: GrantFiled: July 21, 2016Date of Patent: August 22, 2017Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.Inventors: Nicolas Tesson, Carmen Jiménez, Llorenç Rafecas, Marta Pontini
-
Publication number: 20160376236Abstract: The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.Type: ApplicationFiled: July 21, 2016Publication date: December 29, 2016Inventors: Nicolas Tesson, Carmen Jiménez, Llorenç Rafecas, Marta Pontini
-
Patent number: 9006424Abstract: The invention concerns a new process for the resolution of ivabradine and of intermediates of synthesis thereof.Type: GrantFiled: July 31, 2012Date of Patent: April 14, 2015Assignee: Laboratorio Chimico Internazionale S.p.A.Inventors: Antonio Nardi, Bruno De Angelis, Paolangelo Cerea, Jane Llorenc Rafecas, Nicolas Tesson
-
Publication number: 20150087686Abstract: It comprises a cocrystal of saxagliptin hydrochloride and a compound selected from the group consisting of saxagliptin, glycolic acid, malonic acid, and urea; or a solvate thereof, or a hydrate thereof. It also comprises a salt of saxagliptin with glycolic acid 1:1 hydrate. It also comprises their preparation processes, as well as their use as antidiabetics.Type: ApplicationFiled: April 24, 2013Publication date: March 26, 2015Applicant: ENANTIA, S.L.Inventors: Nicolas Tesson, Montserrat Trilla Castaño, Lydia Cárdenas Romaña, Llorenç Rafecas Jané
-
Publication number: 20140357859Abstract: The invention concerns a new process for the resolution of ivabradine and of intermediates of synthesis thereof.Type: ApplicationFiled: July 31, 2012Publication date: December 4, 2014Applicant: LOBORATORIO CHIMICO INTERNAZIONALE S.p.A.Inventors: Antonio Nardi, Bruno De Angelis, Paolangelo Cerea, Jane Llorenc Rafecas, Nicolas Tesson
-
Publication number: 20140303344Abstract: The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followed by a hydrolysis reaction to obtain L-mesityl alanine, alternatively its enantiomer D-mesityl alanine and, optionally, subjecting said compound to an amino group protection reaction, particularly as Fmoc. It also comprises Fmoc-L- or Fmoc-D- mesityl alanine as products per se, useful as intermediates in preparing peptides or peptide analogs with therapeutic or biological activity.Type: ApplicationFiled: March 12, 2014Publication date: October 9, 2014Applicant: BCN PÉPTIDES, S.A.Inventors: Llorenç RAFECAS JANE, Antoni RIERA ESCALE, Rosario RAMON ALBALATE, Monica ALONSO XALMA
-
Patent number: 8815862Abstract: Methods for the preparation of Rosuvastatin by co-crystals of Rosuvastatin or intermediates are provided. Also provided are co-crystals, pharmaceutical compositions which include such co-crystals and methods for treating conditions associated with hypercholesterolemia by administering such compositions.Type: GrantFiled: December 3, 2012Date of Patent: August 26, 2014Assignee: F.I.S. Fabbrica Italiana Sintetici S.p.A.Inventors: Clark Ferrari, Andrea Castellin, Marco Galvagni, Nicolas Tesson, Jordi De Mier, Llorenç Rafecas
-
Patent number: 8791294Abstract: The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followed by a hydrolysis reaction to obtain L-mesityl alanine, alternatively its enantiomer D-mesityl alanine and, optionally, subjecting said compound to an amino group protection reaction, particularly as Fmoc. It also comprises Fmoc-L- or Fmoc-D-mesityl alanine as products per se, useful as intermediates in preparing peptides or peptide analogs with therapeutic or biological activity.Type: GrantFiled: November 19, 2008Date of Patent: July 29, 2014Assignee: BCN Peptides, S.A.Inventors: Llorenç Rafecas Jane, Antoni Riera Escale, Rosario Ramon Albalate, Monica Alonso Xalma
-
Publication number: 20120283434Abstract: A process for the preparation of rivaroxaban, or a pharmaceutically acceptable salt thereof, or a solvate thereof, including a hydrate, comprising submitting an amine compound of formula (III) wherein R1 is a (C4-C10)-alkyl radical which is attached to the N atom by a tertiary C atom, first to an acylation reaction and then to a dealkylation reaction.Type: ApplicationFiled: January 3, 2011Publication date: November 8, 2012Applicant: ENANTIA, S.L.Inventors: Llorenç Rafecas Jané, Alexander Christian Comely, Alessandro Ferrali, Celia Amela Cortés, Mireia Pastó Aguilà
-
Patent number: 8093398Abstract: It comprises a process for the production of delmopinol or a pharmaceutically acceptable salt and/or a solvate thereof, by subjecting the compound of formula (II) where R1 and R2 are the same or different, independently selected from the group consisting of H, (C1-C6) alkyl or, alternatively, R1 and R2 form, together with the carbon atom to which they are attached, a (C5-C6) cycloalkyl radical; and R3 is a radical selected from the group consisting of CF3, (C1-C4) alkyl, phenyl, and phenyl mono- or disubstituted by a radical selected from the group consisting of (C1-C4)-alkyl, halogen and nitro to a deprotection and cyclisation reaction. The process is useful to prepare delmopinol or its salts on an industrial scale. The compound of formula (II) is new and also forms part of the present invention, as well as its preparation process and other new intermediates of said preparation process.Type: GrantFiled: December 20, 2010Date of Patent: January 10, 2012Assignee: Sinclair Pharmaceticals LimitedInventors: Alexander Comely, Llorenç Rafecas Jane, Nicolas Tesson, Antoni Riera Escale
-
Publication number: 20110105443Abstract: The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses for the treatment of various disorders, including pain.Type: ApplicationFiled: March 6, 2009Publication date: May 5, 2011Applicant: LABORATORIES DEL DR. ESTEVE, S.A.Inventors: Helmut Heinrich Buschmann, Nicolas Tesson, Joan Farran, Llorenc Rafecas
-
Publication number: 20110082301Abstract: It comprises a process for the production of delmopinol or a pharmaceutically acceptable salt and/or a solvate thereof, by subjecting the compound of formula (II) where R1 and R2 are the same or different, independently selected from the group consisting of H, (C1-C6) alkyl or, alternatively, R1 and R2 form, together with the carbon atom to which they are attached, a (C5-C6) cycloalkyl radical; and R3 is a radical selected from the group consisting of CF3, (C1-C4) alkyl, phenyl, and phenyl mono- or disubstituted by a radical selected from the group consisting of (C1-C4)-alkyl, halogen and nitro to a deprotection and cyclisation reaction. The process is useful to prepare delmopinol or its salts on an industrial scale. The compound of formula (II) is new and also forms part of the present invention, as well as its preparation process and other new intermediates of said preparation process.Type: ApplicationFiled: December 20, 2010Publication date: April 7, 2011Inventors: Alexander Comely, Llorenç Rafecas Jane, Nicolas Tesson, Antoni Riera Escale
-
Patent number: 7902355Abstract: A process for the preparation of an 11-(4-substituted-1-piperazinyl)dibenzo[b,f][1,4]thiazepine derivative, of general Formula (I), where A is hydrogen or a —(CH2)2—OH group or a —(CH2)2-0-(CH2)2—OH group, or of a salt thereof, comprises a step in which 10H-dibenzo[b,f][1,4]thiazepin-11-one is reacted with a piperazine derivative in the presence of a titanium alkoxide of general formula Ti(OR)4, where R is a straight or branched alkyl group, having from one to eight carbon atoms to obtain said Formula I derivative or a salt thereof. Where A is —CH2)2-0-(CH2)2—OH, then the piperazine derivative is 1-(2-(2-hydroxyethoxy)ethyl)piperazine and the 11-(4-substituted-1-piperazinyl)dibenzo[b,f][1,4]thiazepine is quetiapine, (11-(4-(2-(2-hydroxyethoxy)ethyl)-1-piperazinyl)dibenzo[b,f][1,4]thiazepine). The process may comprise an additional step of reacting the quetiapine with fumaric acid to obtain quetiapine hemifumarate.Type: GrantFiled: December 21, 2005Date of Patent: March 8, 2011Assignee: Union Quimico-Farmaceutica S.A.Inventors: Alexander Christian Comely, Francesc Xavier Verdaguer Espaulella, Llorenç Rafecas Jané, Antonio Domingo Coto
-
Patent number: 7893258Abstract: It comprises a preparation process of delmopinol or a pharmaceutically acceptable salt and/or a solvate thereof, by submitting the compound of formula (II) where R1 and R2 are the same or different, independently selected from the group consisting of H, (C1-C6)-alkyl or, alternatively, R1 and R2 form, together with the carbon atom to which they are attached, a (C5-C6)-cycloalkyl radical; and R3 is a radical selected from the group consisting of CF3, (C1-C4)-alkyl, phenyl, and phenyl mono- or disubstituted by a radical selected from the group consisting of (C1-C4)-alkyl, halogen and nitro to a deprotection and cyclisation reaction. The process is useful to prepare delmopinol or its salts on an industrial scale. The compound of formula (II) is new and also forms part of the present invention, as well as its preparation process and other new intermediates of said preparation process.Type: GrantFiled: January 10, 2007Date of Patent: February 22, 2011Assignee: Sinclair Pharmaceuticals LimitedInventors: Alexander Comely, Llorenç Rafecas Jane, Nicolas Tesson, Antoni Riera Escale
-
Publication number: 20110040115Abstract: Process for the preparation of aromatic derivatives of 1-adamantane (tricyclo[3.3.1.1 (3,7)]decane), or an acceptable pharmaceutical salt thereof, based on a hydrolysis reaction of a precursor cyano compound. It also comprises different processes for obtaining the cyano compound. It is especially useful for obtaining Adapalene on an industrial scale in high yield and purity. It also comprises new intermediates useful in said preparation process.Type: ApplicationFiled: December 1, 2006Publication date: February 17, 2011Applicant: FINORGA SASInventors: Alexander Christian Comely, Marta Marfil Sánchez, Llorenc Rafecas Jané, Antoni Riera Escalé
-
Publication number: 20100298538Abstract: The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followed by a hydrolysis reaction to obtain L-mesityl alanine, alternatively its enantiomer D-mesityl alanine and, optionally, subjecting said compound to an amino group protection reaction, particularly as Fmoc. It also comprises Fmoc-L- or Fmoc-D-mesityl alanine as products per se, useful as intermediates in preparing peptides or peptide analogs with therapeutic or biological activity.Type: ApplicationFiled: November 19, 2008Publication date: November 25, 2010Applicant: BCN PÉPTIDES, S.A.Inventors: Llorenç Rafecas Jane, Antonio Riera Escale, Rosario Ramon Albalate, Monica Alonso Xalma
-
Patent number: 7799925Abstract: A process for the preparation of (S)-omeprazole from racemic omeprazole via the formation of an inclusion complex with (S)-1,1,2-triphenyl-1,2-ethanediol. (S)-Omeprazole is recovered in a substantially optically pure form either in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. The (S)-omeprazole 2[(S)-1,1,2-triphenyl-1,2-ethanediol] inclusion complex is new. This resolution process proceeds with high yields and high optical purity.Type: GrantFiled: December 18, 2006Date of Patent: September 21, 2010Assignee: Unión Químico Farmacéutica, S.A.Inventors: Antonio Domingo Coto, Alexander Comely, Xavier Verdaguer Espaulella, Llorenç Rafecas Jané
-
Publication number: 20100010265Abstract: Process for the obtaining of 1-adamantane (tricycle[3.3.1.1 (3,7)]decane) derivatives, or of a pharmaceutically acceptable salt thereof, based on a carboxylation reaction, via metallation, of a precursor compound with an adequate leaving group. It also comprises the preparation of the precursor compound by means of a selective coupling of the corresponding boron, magnesium or zinc derivative with the corresponding disubstitute aromatic derivative. It is especially useful for the obtaining of Adapalene at industrial scale with good yield and high purity.Type: ApplicationFiled: September 21, 2009Publication date: January 14, 2010Inventors: Alexander Christian Comely, Marta Marfil Sanchez, Llorenc Rafecas Jane, Xavier Verdaguer Espaulella
-
Patent number: 7645910Abstract: Process for the obtaining of 1-adamantane (tricycle[3.3.1.1 (3,7)]decane) derivatives, or of a pharmaceutically acceptable salt thereof, based on a carboxylation reaction, via metallation, of a precursor compound with an adequate leaving group. It also comprises the preparation of the precursor compound by means of a selective coupling of the corresponding boron, magnesium or zinc derivative with the corresponding disubstitute aromatic derivative. It is especially useful for the obtaining of Adapalene at industrial scale with good yield and high purity.Type: GrantFiled: December 1, 2006Date of Patent: January 12, 2010Assignee: Finorga SASInventors: Alexander Christian Comely, Marta Marfil Sánchez, Llorenç Rafecas Jané, Xavier Verdaguer Espaulella
-
Publication number: 20090137841Abstract: Process for the obtaining of 1-adamantane (tricycle[3.3.1.1 (3,7)]decane) derivatives, or of a pharmaceutically acceptable salt thereof, based on a carboxylation reaction, via metallation, of a precursor compound with an adequate leaving group. It also comprises the preparation of the precursor compound by means of a selective coupling of the corresponding boron, magnesium or zinc derivative with the corresponding disubstitute aromatic derivative. It is especially useful for the obtaining of Adapalene at industrial scale with good yield and high purity.Type: ApplicationFiled: December 1, 2006Publication date: May 28, 2009Inventors: Alexander Christian Comely, Marta Marfil Sanchez, Llorenc Rafecas Jane, Xavier Verdaguer Espaulella